PARIS, June 25 (Reuters) – French drugmaker Sanofi
is in the “very early stages” of considering the sale of a
portfolio of older drugs, managers told an internal meeting on
Wednesday, according to union representatives who were present.
People familiar with the matter had told Reuters in April
that Sanofi was looking to part with drugs that could fetch $7-8
billion as it seeks to shed non-core assets and focus on
PARIS, June 25 (Reuters) – Eighteen French biotech firms,
several newly listed on the Paris stock market, head to New York
on Wednesday and Thursday to convince U.S. investors to help
fund the next stages of their research and development.
Among them are companies specialised in therapeutic vaccines
(Genticel ), cell-based immunotherapy (TxCell
), genetic disease diagnostics (Genomic Vision
) and needle-free injections (Crossject ).
PARIS, May 28 (Reuters) – Europe’s third-largest catering
group Elior said it aimed to raise at least 845 million euros
($1.2 billion) in a mid-June initial public offering (IPO) and
would use the proceeds to cut debt and fund further expansion,
notably in the United States.
The company, which competes with France’s Sodexo
and Britain’s Compass, set a price range for its IPO of
14.35 to 17.50 euros per share on Wednesday and set an expected
June 11 date for its return to the Paris bourse after an
PARIS, April 10 (Reuters) – France is going out on a limb
with a plan to push the use of cheap copies of biotech drugs,
triggering alarm among companies in Europe’s second-biggest
pharmaceutical market behind Germany.
The government quietly introduced the measure allowing
pharmacists to substitute prescribed brand-name biotech drugs
with cheaper, similar versions in its 2014 healthcare budget.
PARIS (Reuters) – Sanofi (SASY.PA: Quote, Profile, Research, Stock Buzz) is on the lookout for acquisitions to boost key business units, such as consumer and animal health products, and expects strong growth in the “strategic continent” of Africa, its chief executive told Reuters on Wednesday.
Chris Viehbacher declined to say whether the group would be interested in Merck & Co’s (MRK.N: Quote, Profile, Research, Stock Buzz) non-prescription consumer business or Novartis’s (NOVN.VX: Quote, Profile, Research, Stock Buzz) animal health operations.
NEUVILLE-SUR-SAONE, France (Reuters) – Sanofi expects final clinical results for its vaccine against dengue by late September, the French drugmaker’s project leader has told Reuters, and has already gambled on starting production despite some disappointing early trials data.
Sanofi has invested more than one billion euros in the project and is hoping to become the first drugmaker to sell such a shot next year after two decades of research on the world’s fastest-growing tropical disease, for which there is no preventative treatment.
PARIS (Reuters) – French diagnostics specialist BioMerieux (BIOX.PA: Quote, Profile, Research, Stock Buzz) will look at the microbiology unit Siemens (SIEGn.DE: Quote, Profile, Research, Stock Buzz) is considering selling, BioMerieux’s Chief Executive told Reuters.
Sources have told Reuters Siemens may sell the business, which makes tools to detect bacteria and test antibiotics and is part of its diagnostics division, and that bankers are pitching it to likely buyers at around $500 million.
PARIS, March 7 (Reuters) – If French food group Danone
decides to sell its slowing medical nutrition business, it is
most likely to invest the proceeds in its faster growth baby
food and dairy businesses, targeting acquisitions in Asia and
Reuters reported last month that the world’s No 1 yoghurt
maker was considering selling the unit which makes tube feeding
and other products, which has been under pressure from declining
healthcare budgets in Europe.
PARIS, March 5 (Reuters) – France’s Stallergenes
said on Wednesday it had appointed former Actelion
manager Christian Chavy as its new chief executive to drive the
company’s expansion into the U.S. immunotherapy market.
Stallergenes is hoping to win by the end of the month a U.S.
green light to launch its immunotherapy pill Oralair for the
treatment of grass allergies.
PARIS, March 4 (Reuters) – Caterer Elior said on Tuesday it
would return to French stock market by the summer after an
eight-year absence, in an estimated 4 billion euro ($5.51
billion) flotation that could be one of the largest on the Paris
bourse this year.
“Elior confirms (it is) preparing a stock market listing on
Euronext Paris by Summer 2014,” a company spokesman said.